全球已邁向AI人工智慧新時代，大數據滲透至各行各業，帶來技術性的變革，增加效率，更提高了科學性的精準度。醫療產業也跨向AI時代，正加速邁向精準醫學的新紀元，精準醫學市場產值2015年約為388.786億美元，預估2023年將會成長到982.504億美元。。
依據精準醫學產業現況分析與未來發展預測，透過個案公司進行深度訪談與分析，以了解產業現況及未來發展變動的趨勢，研究目的：
一、 精準醫學產業現況分析。
二、 深入探討個案公司經營模式。
三、 研擬個案公司策略方向與營運方針。
四、 擴展海外營業據點之可行性。
本研究範圍以臺灣精準醫學產業前三大的市佔率的公司為個案研究範圍，研究結果：
一、 依據BCG四象限分類法，屬於四象限中的明星產品。
二、 個案公司營運持續成長，持續研發新產品，提升市占率。
三、 採合資方案，增加資金來源。
四、 布局東南亞及大陸市場。
The world has moved towards a new era of AI artificial intelligence. Big data has penetrated into all walks of life, bringing about technological changes, increasing efficiency, and improving scientific precision. The medical industry is also moving towards the AI era, and is accelerating the new era of precision medicine. The output value of the precision medicine market is about 38.786 billion US dollars in 2015, and it is estimated that it will grow to 98.254 billion US dollars in 2023. .
Based on the current situation analysis and future development forecast of the precision medical industry, through in-depth interviews and analysis by case companies to understand the current situation of the industry and the trend of future development changes, the research purposes:
1. the analysis of the current situation of the precision medicine industry.
2. in-depth discussion of the case company business model.
3. develop the case strategy and operation policy of the case company.
4. the feasibility of expanding overseas business locations.
The scope of this study is based on the top three market share companies in Taiwan's precision medicine industry. The results of the study are:
1. according to the BCG four-quadrant classification, it belongs to the star products in the four quadrants.
2. the case company's operation continued to grow, continued to develop new products, and increase market share.
3. adopt a joint venture program to increase the source of funds.
4. the layout of Southeast Asia and the mainland market.
